BOSTON, Mass. ( TheStreet) -- The year is coming to an end but the biotech calendar is still buzzing with important, stock-moving events right up to New Year's Eve.

Before I get to the calendar, I want to mention some key December biotech catalysts without a fixed date but which investors should still be keeping in mind.

Delcath Systems ( DCTH) is supposed to complete the U.S. approval application for its liver tumor Chemosaturation System before the end of the month. RXi Pharmaceuticals ( RXII) has promised investors a significant drug development partnership before year's end. Investors will also be eager to hear the outcome of the December meeting between Arena Pharmaceuticals ( ARNA) and FDA following the latter's rejection of Arena's obesity drug lorcaserin.

Cell Therapeutics ( CTIC) is expecting a ruling on its appeal of the FDA's rejection of the company's lymphoma drug pixantrone. Amgen ( AMGN) will announce results from a phase III trial investigating whether treatment with Xgeva can prevent the spread of prostate cancer to the bone. Incyte Pharmaceuticals ( INCY) is expected to announce top-line results from a U.S. phase III study of INCB18424 in myelofibrosis.

Celgene ( CELG) could have data from two important, phase III clinical trials before the books close on 2010: A phase III study of Abraxane in front-line non-small cell lung cancer and a phase III study of Amrubicin in small-cell lung cancer (although this latter study may not be completed until early 2011.)

Corcept Therapeutics ( CORT) will announce top-line results from a phase III study of Corlux in Cushing's Syndrome during December.

Now, to the December biotech calendar:

Dec. 2:

Affymax ( AFFY) provides an update on regulatory plans for the experimental anemia dru Hematide.

Exelixis ( EXEL) investor/analyst meeting.

Targacept ( TRGT) investor/analyst meeting.

Dec. 3:

Orexigen Therapeutics ( OREX): FDA should release review documents on the obesity drug Contrave in advance of the advisory panel meeting.

Dec. 4-7:

American Society of Hematology annual meeting: Important data presentations from Onyx Pharmaceuticals ( ONXX), Seattle Genetics ( SGEN), Celgene, and others.

Dec. 5-9:

American College of Neuropsychopharmacology (ACNP) annual meeting.

Dec. 7:

Orexigen Therapeutics: FDA advisory panel reviewing the obesity drug Contrave. I'll be live-blogging the Contrave panel, sign up below for an email reminder.

Dec. 8-12:

San Antonio Breast Cancer Symposium

If you liked this article you might like

Alaska Air, Corcept Therapeutics, First Solar: 'Mad Money' Lightning Round

Markets Focus on Business: Cramer's 'Mad Money' Recap (Monday 8/28/17 )

Corcept Therapeutices Eyes Another Double

5 Stocks Under $10 That Could Make You a Lot of Money

Everybody's Doing It: 5 Stocks Under $10 That I Like